Euclid Transactional confirms Asia Pacific launch
August 29 2024 by Kristina Shperlik
-
India deal activity drives demand for W&I cover, competition in Singapore
- September 4
The increasing deal flow combined with ample insurance capacity and more scrutinised approach to risk in the country means more underwriters are likely to enter the M&A insurance space over the next six months.
-
Marsh elevates Eliza Grant to head of transactional risk for Pacific
- August 9
Sydney-based Grant joined Marsh in 2021 as a senior transactional risk advisor for private equity and M&A.
-
Dual expands into W&I insurance in ANZ with new team led by Jordan Schwarz
- August 8
The MGA’s new transaction solutions capability is an expansion to its title insurance offering in the region launched in April this year.
-
Tax breaches main driver of APAC M&A insurance losses in 2023: Marsh
- August 8
While tax accounted for 32% of all W&I claim notifications in the region last year, other categories such as compliance (15%), employment (15%), and material contracts (23%) are also becoming more frequent.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
